Endometrial Scratching Before IVF: Is It Worth Adding After a Failed Transfer?

A failed embryo transfer can make any proposed extra step sound reassuring. Endometrial scratching is often described as preparing a receptive surface for the embryo. The theory is understandable, but decisions should be made using patient-relevant outcomes such as live birth, not the appeal of a biological explanation alone. The procedure also adds a clinical visit and can be uncomfortable.

Endometrial scratching involves deliberately causing minor injury to the womb lining, generally using an instrument in a clinical setting. The suggested mechanism is a repair response that could affect implantation. This is a hypothesis rather than proof of benefit in an individual cycle. Scratching is not the same as a diagnostic biopsy, hysteroscopy or treatment of a polyp. If another procedure is indicated, the clinician should identify its diagnostic or treatment purpose separately.

The HFEA review reports conflicting evidence for whether scratching improves birth outcomes among most IVF patients and insufficient evidence to rate benefit in recurrent implantation failure. That does not mean an individual procedure is always harmful, but it does mean a patient should not be told it has been proven to increase their chances. Ask whether the evidence comes from randomised trials, which patient group was studied and what comparator was used.

Even a short office procedure may cause pain, spotting or anxiety; it also has logistical and financial costs. The clinic should explain any infection-related precautions, contraindications and what symptoms warrant medical review. A discounted add-on bundle is not a clinical indication. Request a separate price for scratching and ask whether the base IVF protocol would otherwise change. Insurance or package inclusion, if any, must be verified rather than assumed.

Before adding another intervention, check whether there was an embryo to transfer, its development and status, the progesterone and transfer protocol, uterine imaging and whether the pregnancy test was done at the right time. One failed transfer does not establish an immune disorder or an endometrial defect. For repeated failure, clinical review becomes more individualised; testing should still have a clear purpose. There is no one universally effective “implantation booster”.

Ask the clinic to specify the exact expected benefit, the evidence for someone with your history, and the risks. Request documentation of why scratching is recommended rather than simply offered as a routine upsell. It is appropriate to decline an uncertain add-on after informed discussion.

There is a meaningful difference between a procedure offered within a carefully defined research protocol and one marketed as a routine solution for every failed cycle. Ask whether a trial exists for the patient group in question, what participation entails and whether charges are compatible with research ethics. Outside research, the clinician should be able to explain both supporting and conflicting evidence and acknowledge uncertainty about benefits. Compare the proposed procedure with simply following an evidence-based transfer protocol and addressing any confirmed uterine abnormality. Patients should know that a diagnostic biopsy may be justified for specific symptoms even if routine scratching for implantation is not. These are different indications, and consent should not blur them. The freedom to decline an optional procedure should not affect respectful access to standard IVF care.

HomeIVF describes a clinician-led approach to fertility care with the possibility of remote counselling and selected home-supported tasks. A home blood collection or injection visit is never automatic: location, suitability, trained staff and escalation procedures must be checked. Core ART treatment stays facility-based, including necessary scans, egg retrieval, sperm handling, embryology, embryo freezing and transfer. The goal is fewer avoidable journeys, not fewer clinically essential checks.

HomeIVF could arrange a clinician-led remote review of the failed cycle and blood testing or prescribed injection support where locally verified. Scratching, if ultimately chosen, requires a clinical facility; it is not a home-based IVF support service. Embryo transfer, ultrasound and embryology likewise require suitable facilities.

Evidence can differ between a biological explanation, a reliable diagnostic method and proof that a proposed treatment improves live birth. Ask which of those claims is being made. A scientifically plausible add-on is not automatically clinically useful, and the clinic should be able to explain benefits, burdens and alternatives in plain language.

Cost planning should follow the recommended medical pathway rather than an advertised package name. Ask for itemised charges for any further consultation, repeat test, ultrasound, medicines, laboratory assessment, anaesthesia, egg retrieval, sperm preparation, ICSI if indicated, storage and transfer. Some of these steps may be irrelevant in your case. A plan that avoids an unhelpful add-on may save both money and invasive care; another patient may genuinely need a specialist procedure. Request the clinic’s cancellation and refund rules and ask which fees are incurred before the result of the next test is known.

Before choosing a treatment date, write down the name of the responsible clinician, the facility for any required procedure, how results will be communicated, and whom to contact when symptoms change. For Endometrial injury before transfer, the records reviewed should be current and the next appointment should have a clear purpose. Discuss when the decision will be revisited rather than treating an estimate or an isolated test as a deadline. If a plan changes, request updated instructions in writing; do not adjust prescribed injections, anticoagulants or hormone support from online advice. Severe pain, fainting, breathing trouble or heavy bleeding needs prompt in-person assessment.